Patients that relapse or are resistant to treatments are classified as high-risk in follicular lymphoma. Here, Nathan Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses how best to identify high risk patients and how to improve their outcome in the long term. Dr Fowler states that currently, there is no biomarker to identify those at risk of relapse, however there are studies being conducted in order to detect one. He also explores the idea of novel targeted therapies such as PI3K inhibitors and CAR T-cell therapy, and how they could potentially improve survival rates in high-risk patients, thus improving their outcome. This was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX.